The following is a summary of “Risks of adverse events with mirtazapine for adults with major depressive disorder: a ...

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

A compelling new study is building on a growing body of evidence showing a common exercise supplement used to build muscle ...

A new study, led by USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI), will explore structural ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...

I’ve been living with depression for almost 12 years. I’m 31 now and I found out I had major depressive disorder when I was 19. I had a miserable freshman year of college, but I didn't really ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...

Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

People with bipolar I disorder have had at least one manic episode preceded or followed by hypomanic or major depressive ...